Brentuximab vedotin for recurrent Hodgkin lymphoma after allogeneic hematopoietic stem cell transplantation: A report from the EBMT Lymphoma Working Party

ConclusionsBV is a safe and effective salvage therapy for patients with HL who develop disease recurrence or progression after undergoing allo ‐SCT, even after prior exposure to BV.
Source: Cancer - Category: Cancer & Oncology Authors: Tags: Original Article Source Type: research